Premium
A multiple‐dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin‐11 (oprelvekin)
Author(s) -
Cotreau Monette M.,
Stonis Lucille,
Strahs Andrew,
Schwertschlag Ullrich S.
Publication year - 2004
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.415
Subject(s) - medicine , tolerability , pharmacokinetics , adverse effect , placebo , pharmacodynamics , pharmacology , gastroenterology , anesthesia , alternative medicine , pathology
A study in healthy men and women was performed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered recombinant human interleukin‐11 (oprelvekin) (OAO). Four cohorts of 10 subjects each received 3, 5, 10 or 30 mg (8:2/OAO:placebo ratio), first as a single dose with a 7‐day washout period, then 7 consecutive daily doses. Safety was assessed by ongoing evaluation of adverse events (AEs) and laboratory values. PK samples were collected on the first and last day of dose administration. The established effects of subcutaneous oprelvekin on C‐reactive protein (CRP, ↑), platelet count (↑), fibrinogen (↑) and hemoglobin (↓), were evaluated. PK analysis showed that most subjects (27/34, 79%) had undetectable serum levels of IL‐11. PD measures showed no changes from baseline between any OAO group and the placebo group. Orally administered oprelvekin was safe and well tolerated at all doses. A total of five AEs (abdominal pain, diarrhea, headache, rhinitis, grade 3 alanine aminotransferase elevation) were reported across all groups. Evaluations of serum IL‐11 levels indicate that OAO is not systemically absorbed at levels above the lower limit of the bioanalytic assay. These data in addition to the lack of effect on PD measures suggest that there is a decreased potential of systemic adverse events with OAO. Copyright © 2004 John Wiley & Sons, Ltd.